Phase II study of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in advanced colorectal carcinoma.
D000328:Adult; D000368:Aged; D003504:Ancitabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003561:Cytarabine / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000188:drug therapy*
D003561:Cytarabine; D003504:Ancitabine